Effects of peptide L2 of human papillomavirus type 16 on the cytokine profile of dendritic cells in vitro

Abstract

BACKGROUND: The human papillomavirus is an etiological factor and a biological carcinogen in tumor lesions and cancer. Currently, there are several known possible mechanisms of immune evasion of human papillomavirus. Therefore, early methods for diagnosing papillomavirus infection and effective treatments.

AIM: To analyze the cytokine profile should be established of dendritic cells in response should be determined to stimulation by peptide L2 of human papillomavirus type 16 in vitro.

METHODS: Dendritic cell cultures were obtained from the blood of donors without signs of the human papillomavirus infection in history. A culture without stimulation was used as a control. As experimental groups, cultures synthesized peptide with L2 of the human papillomavirus type 16 were used. Enzyme-linked immunosorbent assay was used to determine the levels of pro- and anti-inflammatory cytokines.

RESULTS: In comparison with spontaneous response in the control group after inoculation with peptide L2 of human papillomavirus type 16, increased IL-10, MCP-1, VEGF, IL-6, and IFN-γ concentrations and significant changes in IL-1β, IL-4, IL-8, IFN-α, and TNF-α concentrations were not detected.

CONCLUSIONS: The results confirm the ability of the human papillomavirus to evade the antiviral immune response by affecting the synthesis of several cytokines.

Keywords

human papillomavirus / cytokines / chemokines / immune evasion / vascular endothelial growth factor

References

[1] Ntanasis-Stathopoulos I, Kyriazoglou A, Liontos M, Dimopoulos MA, Gavriatopoulou M. Current trends in the management and prevention of human papillomavirus (HPV) infection. J BUON. 2020;25(3):1281–1285.

[2] Ntanasis-Stathopoulos I., Kyriazoglou A., Liontos M., Dimopoulos M.A., Gavriatopoulou M. Current trends in the management and prevention of human papillomavirus (HPV) infection // J BUON. 2020. Vol. 25, N 3. P. 1281–1285.

[3] Hong S, Laimins LA. Manipulation of the innate immune response by human papillomaviruses. Virus Research. 2017;231:34–40. doi: 10.1016/j.virusres.2016.11.004

[4] Hong S., Laimins L.A. Manipulation of the innate immune response by human papillomaviruses // Virus Research. 2017. Vol. 231. P. 34–40. doi: 10.1016/j.virusres.2016.11.004

[5] Lefkowitz EJ, Dempsey DM, Hendrickson RC, et al. Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV). Nucleic Acids Research. 2018;46(D1):D708–D717. doi: 10.1093/nar/gkx932

[6] Lefkowitz E.J., Dempsey D.M., Hendrickson R.C., et al. Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV) // Nucleic Acids Research. 2018. Vol. 46, N D1. P. D708–D717. doi: 10.1093/nar/gkx932

[7] Brockmann L, Soukou S, Steglich B, Czarnewski P. Molecular and functional heterogeneity of IL-10-producing CD4+ T cells. Nature Communications. 2018;9(1):5457. doi: 10.1038/s41467-018-07581-4

[8] Brockmann L., Soukou S., Steglich B., Czarnewski P. Molecular and functional heterogeneity of IL-10-producing CD4+ T cells // Nature Communications. 2018. Vol. 9, N 1. P. 5457. doi: 10.1038/s41467-018-07581-4

[9] Rojas-Sepúlveda DA, Gleisner A, Pereda C, López M, Onfray FS. Tumor lysate loaded dendritic cells induce a Tcell specific antitumor response against gallbladder cancer. Journal of Immunology. 2017;198 Suppl. 1(79):18–79. doi: 10.4049/jimmunol.198.Supp.79.18

[10] Rojas-Sepúlveda D.A., Gleisner A., Pereda C., López M., Onfray F.S. Tumor lysate loaded dendritic cells induce a T cell specific antitumor response against gallbladder cancer // Journal of Immunology. 2017. Vol. 198, Suppl. 1, N 79. P. 18–79. doi: 10.4049/jimmunol.198.Supp.79.18

[11] Skelin J, Sabol I, Tomaić V. Do or Die: HPV E5, E6 and E7 in Cell Death Evasion. Pathogens. 2022;11(9):1027. doi: 10.3390/pathogens11091027

[12] Skelin J., Sabol I., Tomaić V. Do or Die: HPV E5, E6 and E7 in Cell Death Evasion // Pathogens. 2022. Vol. 11, N 9. P. 1027. doi: 10.3390/pathogens11091027

[13] Garg AD, Vara Perez M, Schaaf M, et al. Trial watch: Dendritic cell-based anticancer immunotherapy. Europe PMC. 2017;6(7): e1328341. doi: 10.1080/2162402X.2017.1328341

[14] Garg A.D., Vara Perez M., Schaaf M., et al. Trial watch: Dendritic cell-based anticancer immunotherapy // Europe PMC. 2017. Vol. 6, N 7. P. e1328341. doi: 10.1080/2162402X.2017.1328341

[15] Gutiérrez-Hoya A, Soto-Cruz I. NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy. Cells. 2021;10(11):3104. doi: 10.3390/cells10113104

[16] Gutiérrez-Hoya A., Soto-Cruz I. NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy // Cells. 2021. Vol. 10, N 11. P. 3104. doi: 10.3390/cells10113104

[17] Nakayama T, Kashiwagi Y, Kawashima H. Long-term regulation of local cytokine production following immunization in mice. Medical Microbiology and Immunology. 2018;62(2):124–131. doi: 10.1111/1348-0421.12566

[18] Nakayama T., Kashiwagi Y., Kawashima H. Long-term regulation of local cytokine production following immunization in mice // Medical Microbiology and Immunology. 2018. Vol. 62, N 2. N 124–131. doi: 10.1111/1348-0421.12566

[19] Zhou B, Lawrence T, Liang Y. The Role of Plasmacytoid Dendritic Cells in Cancers. Frontiers in Immunology. 2021;12:749190. doi: 10.3389/fimmu.2021.749190

[20] Zhou B., Lawrence T., Liang Y. The Role of Plasmacytoid Dendritic Cells in Cancers // Frontiers in Immunology. 2021. Vol. 12. P. 749190. doi: 10.3389/fimmu.2021.749190

[21] Bryant C, Fromm PD, Kupresanin F, et al. A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset. Immunology and Cell Biology. 2016;94(5):447–457. doi: 10.1038/icb.2015.116

[22] Bryant C., Fromm P.D., Kupresanin F., et al. A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset // Immunology and Cell Biology. 2016. Vol. 94, N 5. P. 447–457. doi: 10.1038/icb.2015.116

[23] Mahendra INB, Prayudi PKA., Putra Dwija IBN, Suwiyoga K. HPV16-E6/E7 Oncogene Mutation and p53 Expression among Indonesian women with cervical Cancer. Asian Pacific Journal of Cancer Prevention. 2022;23(8):2705–2711. doi: 10.31557/APJCP.2022.23.8.2705

[24] Mahendra I.N.B., Prayudi P.K.A., Putra Dwija I.B.N., Suwiyoga K. HPV16-E6/E7 Oncogene Mutation and p53 Expression among Indonesian women with cervical Cancer // Asian Pacific Journal of Cancer Prevention. 2022. Vol. 23, N 8. P. 2705–2711. doi: 10.31557/APJCP.2022.23.8.2705

[25] Boyum A. Separation of leukocytes from blood and bone marrow. Scandinavian Journal of Clinical and Laboratory Investigation. 1968;21 Suppl. 97:77–89.

[26] Boyum A. Separation of leukocytes from blood and bone marrow // Scandinavian Journal of Clinical and Laboratory Investigation. 1968. Vol. 21, Suppl. 97. P. 77–89.

[27] Sadri Nahand J, Moghoofei M, Salmaninejad A, et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review. International Journal of Cancer. 2020;146(2):305–320. doi: 10.1002/ijc.32688

[28] Sadri Nahand J., Moghoofei M., Salmaninejad A., et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review // International Journal of Cancer. 2020. Vol. 146, N 2. P. 305–320. doi: 10.1002/ijc.32688

[29] Kleine-Lowinski K, Rheinwald JG, Fichorova RN, et al. Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. International Journal of Cancer. 2003;107(3):407–415. doi: 10.1002/ijc.11411

[30] Kleine-Lowinski K., Rheinwald J.G., Fichorova R.N., et al. Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells // International Journal of Cancer. 2003. Vol. 107, N 3. P. 407–415. doi: 10.1002/ijc.11411

[31] Yang X, Cheng Y, Li C. The role of TLRs in cervical cancer with HPV infection: a review. Signal Transduction and Targeted Therapy. 2017;2:17055. doi: 10.1038/sigtrans.2017.55

[32] Yang X., Cheng Y., Li C. The role of TLRs in cervical cancer with HPV infection: a review // Signal Transduction and Targeted Therapy. 2017. Vol. 2. P. 17055. doi: 10.1038/sigtrans.2017.55

[33] Song SH, Lee JK, Seok OS, Saw HS. The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix. Gynecologic Oncology. 2007;104(3):732–738. doi: 10.1016/j.ygyno.2006.10.054

[34] Song S.-H., Lee J.K., Seok O.-S., Saw H.-S. The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix // Gynecologic Oncology. 2007. Vol. 104, N 3. P. 732–738. doi: 10.1016/j.ygyno.2006.10.054

[35] Yuan Y, Min SJ, Xu DQ, et al. Expressions of VEGF and miR-21 in tumor tissues of cervical cancer patients with HPV infection and their relationships with prognosis. European Review for Medical and Pharmacological Science. 2018;22(19):6274–6279. doi: 10.26355/eurrev_201810_16035

[36] Yuan Y., Min S.-J., Xu D.-Q., et al. Expressions of VEGF and miR-21 in tumor tissues of cervical cancer patients with HPV infection and their relationships with prognosis // European Review for Medical and Pharmacological Science. 2018. Vol. 22, N 19. P. 6274–6279. doi: 10.26355/eurrev_201810_16035

Funding

«Изучение эффективности клеточного иммунного ответа у ВИЧ-позитивных лиц, инфицированных вирусом папилломы человека»“Study of the effectiveness of cellular immune response in HIV-positive individuals infected with human papillomavirus”(122040600157-0)

RIGHTS & PERMISSIONS

Boeva K.A., Malyshkina G.V., Vyalykh I.V.